Pfizer Aktie

20,46 EUR -0,30 EUR -1,45 %

02.06.2025

STU

23,43 USD -0,03 USD -0,13 %

nachbörslich01:25:50

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.116,69 Mrd. EUR

KGV18,83Div. Rendite6,37%

WKN852009

ISINUS7170811035

SymbolPFE

Pfizer Aktien News

Sortieren:Datum Meistgelesen

16.03.23BusinesswireFDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™

14.03.23PR NewswireSHAREHOLDER ALERT: Weiss Law Investigates Seagen Inc.

14.03.23PR NewswireAstellas Announces Phase 3 China ARCHES Study of XTANDI® Meets Primary Endpoint

13.03.23BusinesswirePfizer Invests $43 Billion to Battle Cancer

10.03.23BusinesswirePfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval

28.02.23BusinesswirePfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults

27.02.23BusinesswirePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

22.02.23BusinesswirePfizer’s Elranatamab Receives FDA and EMA Filing Acceptance

21.02.23BusinesswireU.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review

16.02.23BusinesswirePfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study

16.02.23BusinesswirePfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults

10.02.23BusinesswireFDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)

09.02.23BusinesswirePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

31.01.23BusinesswirePFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE

17.01.23BusinesswirePfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries

06.01.23BusinesswireU.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children

03.01.23BusinesswirePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

28.12.22BusinesswireU.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents

21.12.22BusinesswirePfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis

20.12.22BusinesswirePfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts

12.12.22MyDividendsPfizer erhöht die Dividende

10.12.22BusinesswirePfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial

09.12.22BusinesswirePfizer Declares First-Quarter 2023 Dividend

08.12.22BusinesswirePfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

07.12.22BusinesswireU.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults

06.12.22BusinesswirePfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease

01.12.22BusinesswirePfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day

28.11.22BusinesswirePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

16.11.22RSSForm 4 78003

14.11.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE

11.11.22BusinesswirePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

09.11.22RSSForm 10-Q 78003

04.11.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE

03.11.22BusinesswirePfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma

01.11.22BusinesswirePFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK

01.11.22BusinesswirePfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate

01.11.22RSSForm 8-K 78003

18.10.22BusinesswirePfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022

13.10.22BusinesswirePfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

12.10.22BusinesswirePfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer News

Pfizer News: auf dieser Seite finden Sie alle Pfizer News und Nachrichten zur Pfizer Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Pfizer News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Pfizer News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.